Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW
  • The company purchased the hand therapy clinics for $3.5 million
  • The clinics are expected to bring in a revenue of $2.7 million

Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW.

The company acquired the hand therapy clinics for $3.5 million.

The clinics will be funded by the company utilising the undrawn debt available under the facility agreement with ANZ and BOQ.

Healthia is an integrated group of health based companies whose mission is to enrich lives of people through world-class health services.

The group includes My FootDr, Allsports Physiotherapy, Extend Rehabilitation, iOrthotics and D.B.S. Medical Supplies.

The company is currently Australasia’s (Australia, New Zealand and neighbouring islands) leading allied health group.

CEO of the company’s physiotherapy branch Tony Ganter is happy with the acquisition.

“The four speciality hand therapy clinics, which provide physiotherapy and occupational therapy for the hand and upper limb, complement our existing nine Extend Hand Therapy clinics in Queensland,” he said.

Hand Therapy is evaluating and treating injuries and conditions in the shoulder, arm, elbow, forearm, wrist and hand.

The clinics are expected to bring in a revenue of $2.7 million.

“We are pleased that we are able to expand these speciality services across the group,” Tony said.

Healthia’s share price has increased 2.37 per cent today and is currently selling shares at $1.08 per share.

HLA by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.